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Abstract
Background: Hypertension is a risk factor for peripheral arterial disease (PAD). Subjects with PAD are at increased
risk of future cardiovascular (CV) events. Resistin is involved in the pathological processes of CV diseases. The aim of
this study is to investigate whether resistin level is correlated with PAD in hypertensive patients.
Methods: One hundred and twenty-four hypertensive patients were enrolled in this study. Ankle-brachial index
(ABI) values were measured using the automated oscillometric method. An ABI value < 0.9 defined the low ABI
group. Anthropometric analysis with waist circumference and body mass index, and fasting serum levels of blood
urea nitrogen, creatinine, glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density
lipoprotein cholesterol, total calcium, phosphorus, and high-sensitivity C-reactive protein (hs-CRP) were measured
using standard enzymatic automated methods. Serum levels of human resistin were determined using a commercially
available enzyme immunoassay.
Results: Eighteen hypertensive patients (14.5%) were included in the low ABI group. Hypertensive patients in
the low ABI group were older (p = 0.043) and had higher serum creatinine (p < 0.001), high-sensitivity C-reactive
protein (hs-CRP; p = 0.013), and resistin (p < 0.001) levels but a lower estimated glomerular filtration rate (p = 0.002)
than patients in the normal ABI group. After the adjustment for factors that were significantly associated with PAD on
multivariate logistic regression analysis, serum resistin (odds ratio [OR], 1.176; 95% confidence interval [CI], 1.028–1.345;
p = 0.018) was also an independent predictor of PAD in hypertensive patients.
Conclusions: A high serum resistin level is an independent predictor of PAD in hypertensive patients.
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Background
Peripheral arterial disease (PAD) is a reflection of sys-
temic atherosclerotic disease, which affected 202 million
people worldwide in 2010 [1]. Although PAD can be
asymptomatic and subclinical, symptomatic PAD is asso-
ciated with reduced functional capacity and decreased
quality of life [2]. PAD is also associated with an in-
creased risk of incident coronary and cerebrovascular
disease morbidity and mortality [2, 3]. The ankle-brachial
index (ABI), the ratio of the systolic blood pressure (SBP)
at the ankle to that in the arm, is non-invasive and
inexpensive and currently used to assess PAD [3]. In a sys-
tematic review study, ABI had a sensitivity of 97% and
specificity of 89% for detecting significant arterial disease
on angiography [4].
Resistin is an adipocyte-derived signaling cysteine-rich
molecule consisting of 114 amino acids [5]. Resistin is
involved in the pathological processes of cardiovascular
(CV) diseases including inflammation, endothelial dys-
function, thrombosis, angiogenesis, and smooth muscle
cell dysfunction [6]. Serum resistin levels were higher in
PAD patients than in healthy controls and an independent
risk factor of PAD in a Chinese study [7]. PAD has been
known to increase the risk of CV morbidity and mortality,
resistin is involved in the pathological processes of CV
diseases, and hypertension is one of the risk factors of
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PAD [2, 3]. The aim of this study is to examine the rela-




From January to December 2012, 124 hypertensive pa-
tients enrolled at a medical center in Hualien, Taiwan.
The blood pressure (BP) of each patient was measured
in the morning by trained staff using standard mercury
sphygmomanometers with appropriate cuff sizes after
sitting for at least 10 min. Systolic BP and diastolic BP
were taken three times at 5-min intervals and averaged
for analysis. Patients were regarded as having hyperten-
sion if they had a systolic BP ≥ 140 mmHg, diastolic
BP ≥ 90 mmHg, or received any anti-hypertensive medi-
cation in the past 2 weeks. Patients were diagnosed
with diabetes mellitus if their fasting plasma glucose
level was ≥126 mg/dL or they had used oral hypoglycemic
medications or insulin [8]. The Protection of the Human
Subjects Institutional Review Board of Tzu-Chi University
and Hospital approved this study. All patients provided in-
formed consent prior to participating in this study. The
patients were excluded if they had an acute infection,
acute myocardial infarction, or pulmonary edema, had a
history of carotid artery stenosis or stroke; used protease-
activated receptor-1 antagonists or warfarin at the time of
blood sampling; or declined to provide informed consent.
Anthropometric analysis
Waist circumference was measured using a tape measure
at the point between the lowest ribs and the hip bones
with the hands on the hips. Participant weight was mea-
sured in light clothing and without shoes to the nearest
0.5 kg, while height was measured to the nearest 0.5 cm.
Body mass index (BMI) was calculated as the weight in
kilograms divided by the height in meters squared [9–11].
Biochemical investigations
Fasting blood samples (approximately 5 mL) were imme-
diately centrifuged at 3000 × g for 10 min. Serum levels
of blood urea nitrogen (BUN), creatinine (Cre), fasting
glucose, total cholesterol (TCH), triglycerides (TG), high-
density lipoprotein cholesterol (HDL-C), low-density lipo-
protein cholesterol (LDL-C), total calcium, phosphorus,
and high-sensitivity C-reactive protein (hs-CRP) were
measured using an autoanalyzer (COBAS Integra 800;
Roche Diagnostics, Basel, Switzerland) [9–11]. Serum levels
of human resistin (SPI-BIO; Montigny le Bretonneux,
France) [12] and intact parathyroid hormone (iPTH; Diag-
nostic Systems Laboratories, Webster, TX, USA) [9–11]
were determined using a commercially available enzyme
immunoassay or enzyme-linked immunosorbent assay, re-
spectively. The estimated glomerular filtration rate (eGFR)
was calculated using the Chronic Kidney Disease Epi-
demiology Collaboration equation.
ABI measurements
Using an oscillometric method, ABI values were measured
using an ABI-form device (VaSera VS-1000; Fukuda
Denshi Co, Ltd, Tokyo, Japan) that automatically and
simultaneously measures BP in both arms and ankles [13].
With the participants lying in the supine position, occlu-
sion and monitoring cuffs were placed tightly around the
four extremities, and an electrocardiogram was recorded
and the heart sounds were measured for at least 10 min.
ABI was calculated as the ratio of the ankle SBP divided
by the arm SBP, and the lower value of the ankle SBP
was used for the calculation. We repeatedly measured
these parameters for both legs of each participant and
expressed the mean values. PAD was diagnosed based
on an ABI < 0.9 [14]. In this study, left or right ABI
values < 0.9 were used to define the low ABI group.
Statistical analysis
Data were tested for normal distribution using the
Kolmogorov–Smirnov test. Normally distributed data
are expressed as mean ± standard deviation and compari-
sons between patients were performed using the Student’s
independent t-test (two-tailed). Non-normally distributed
data were expressed as medians and interquartile ranges
and comparisons between patients were performed using
the Mann–Whitney U test (TG, fasting glucose, iPTH, hs-
CRP, and resistin). Data expressed as the number of
patients were analyzed by the χ2 test. Because TG, fasting
glucose, iPTH, hs-CRP, and resistin was not normally
distributed and underwent base 10 logarithmic transfor-
mations to achieve normality. Clinical variables that corre-
lated with serum resistin levels in hypertensive patients
were evaluated using univariate linear regression analysis.
Variables that were significantly associated with resistin
levels in hypertensive patients were tested for inde-
pendence on multivariate forward stepwise regression
analysis. Variables that were significantly associated
with PAD were tested for independence on multivariate
logistic regression analysis (adapted factors: smoking,
age, Cre, eGFR, hs-CRP, and resistin). The receiver operat-
ing curve (ROC) was used to calculate the area under the
curve (AUC) to identify the cutoff value of resistin pre-
dicting PAD in hypertensive patients. Data were analyzed
using SPSS for Windows (version 19.0; SPSS Inc., Chicago,
IL, USA). P values < 0.05 were considered statistically
significant.
Results
The clinical and laboratory characteristics of the 124
hypertensive patients are shown in Table 1. Sixty-three
patients (50.8%) had diabetes mellitus and 99 patients
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(79.8%) had dyslipidemia. Eighteen hypertensive patients
(14.5%) were included in the low ABI group. Patients in
the low ABI group were older (p = 0.043) and had higher
serum Cre (p < 0.001), hs-CRP (p = 0.013), and resistin
(p < 0.001) levels but had lower eGFR (p = 0.002) levels
than those in the normal ABI group. Current smokers
among low ABI group were significantly higher than the
normal ABI group (p = 0.031). The use of drugs included
angiotensin-converting enzyme inhibitors (ACEi; n = 44;
35.5%), angiotensin receptor blockers (ARB; n = 67; 54.0%),
β-blockers (n = 72; 58.1%), calcium channel blockers (CCB;
n = 56; 45.2%), statins (n = 69; 55.4%), fibrate (n = 30;
24.2%), aspirin (n = 72; 58.1%), and clopidogrel (n = 30;
24.2%). There was no statistically significant difference
Table 1 Clinical variables of the 124 hypertensive patients in the normal or low ankle brachial index group
Characteristic All patients (n = 124) Normal ABI group (n = 106) Low ABI group (n = 18) p value
Age (years) 64.40 ± 9.81 63.67 ± 9.00 68.72 ± 13.15 0.043*
Height (cm) 161.33 ± 8.84 161.75 ± 8.62 158.83 ± 9.92 0.197
Body weight (kg) 69.96 ± 12.49 70.51 ± 12.78 66.78 ± 10.39 0.243
Waist circumference (cm) 91.87 ± 9.00 91.63 ± 8.52 93.28 ± 11.65 0.476
Body mass index (kg/m2) 26.80 ± 3.72 26.84 ± 3.69 26.53 ± 3.96 0.740
Left ankle-brachial index 1.06 ± 0.11 1.09 ± 0.08 0.87 ± 0.10 <0.001*
Right ankle-brachial index 1.05 ± 0.12 1.08 ± 0.08 0.84 ± 0.10 <0.001*
Systolic blood pressure (mmHg) 134.63 ± 16.97 133.62 ± 16.11 140.56 ± 20.92 0.109
Diastolic blood pressure (mmHg) 74.10 ± 10.18 74.30 ± 10.46 72.94 ± 8.47 0.603
Total cholesterol (mg/dL) 174.18 ± 38.59 174.38 ± 40.54 173.00 ± 24.90 0.889
Triglyceride (mg/dL) 128.00 (93.25–177.25) 122.00 (90.75–178.25) 137.00 (114.00–172.50) 0.383
HDL-C (mg/dL) 45.19 ± 12.81 45.38 ± 12.85 44.11 ± 12.88 0.700
LDL-C (mg/dL) 103.19 ± 30.46 103.03 ± 32.11 104.11 ± 18.47 0.890
Fasting glucose (mg/dL) 111.00 (96.25–137.75) 111.00 (96.75–137.25) 110.00 (94.50–154.00) 0.980
Blood urea nitrogen (mg/dL) 17.36 ± 6.11 16.99 ± 5.75 19.56 ± 7.76 0.100
Creatinine (mg/dL) 1.13 ± 0.33 1.09 ± 0.28 1.38 ± 0.47 <0.001*
eGFR (mL/min) 67.81 ± 20.37 70.10 ± 18.81 54.33 ± 24.35 0.002*
Total calcium (mg/dL) 9.16 ± 0.37 9.15 ± 0.38 9.20 ± 0.33 0.560
Phosphorus (mg/dL) 3.55 ± 0.51 3.54 ± 0.53 3.57 ± 0.38 0.854
Intact parathyroid hormone (pg/mL) 46.65 (33.53–61.95) 46.30 (32.40–59.85) 51.20 (36.45–77.78) 0.272
hs-CRP (mg/dL) 0.21 (0.15–0.29) 0.20 (0.14–0.27) 0.28 (0.20–0.55) 0.013*
Resistin (ng/mL) 7.19 (5.21–10.33) 6.67 (4.77–8.59) 11.79 (9.94–16.72) <0.001*
Male, n (%) 82 (66.1) 71 (67.0) 11 (61.1) 0.627
Diabetes, n (%) 63 (50.8) 52 (49.1) 11 (61.1) 0.344
Dyslipidemia, n (%) 99 (79.8) 85 (80.2) 14 (77.8) 0.814
Smoking, n (%) 11 (8.9) 7 (6.6) 4 (22.2) 0.031*
ACE inhibitor use, n (%) 44 (35.5) 39 (36.8) 5 (27.8) 0.460
ARB use, n (%) 67 (54.0) 57 (53.8) 10 (55.6) 0.888
β-blocker use, n (%) 72 (58.1) 60 (56.6) 12 (66.7) 0.424
CCB use, n (%) 56 (45.2) 49 (46.2) 7 (38.9) 0.563
Statin use, n (%) 69 (55.4) 58 (54.7) 11 (61.1) 0.614
Fibrate use, n (%) 30 (24.2) 28 (26.4) 2 (11.1) 0.161
Aspirin, n (%) 72 (58.1) 64 (60.4) 8 (44.4) 0.205
Clopidogrel, n (%) 30 (24.2) 27 (25.5) 3 (16.7) 0.420
Values for continuous variables are shown as mean ± standard deviation after analysis by Student’s t-test; variables not normally distributed are shown as median
and interquartile range after analysis by the Mann–Whitney U test; values are presented as number (%) and analysis after analysis by the chi-square test
ABI ankle brachial index, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate,
hs-CRP high-sensitivity C-reactive protein, ACE angiotensin-converting enzyme, ARB angiotensin-receptor blocker, CCB calcium-channel blocker
*Values of p < 0.05 were considered statistically significant
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based on gender, co-existing diabetes or dyslipidemia,
or use of ACEi, ARB, β-blockers, CCB, statins, fibrate,
aspirin, or clopidogrel between the two groups. The
resistin levels also did not differ statistically based on
gender, co-existing diabetes or dyslipidemia, or ACEi,
ARB, β-blocker, CCB, statin, fibrate, aspirin, or clopido-
grel use (Table 2).
Uni- and multivariate linear analyses of the clinical
variables associated with serum resistin levels in hyperten-
sive patients are shown in Table 3. Waist circumference
(r = 0.261; p = 0.003), TCH (r = 0.182; p = 0.043), LDL-C
(r = 0.190; p = 0.035), BUN (r = 0.237; p = 0.008), Cre (r =
0.298; p = 0.001), and logarithmically transformed hs-CRP
(log-hs-CRP, r = 0.294; p = 0.001) were positively corre-
lated, while eGFR (r = −0.278; p = 0.002) was negatively
correlated with serum resistin levels in hypertensive pa-
tients. Multivariate forward stepwise linear regression ana-
lysis of the variables significantly associated with fasting
serum resistin levels revealed that waist circumference
(β = 0.204; p = 0.014), LDL-C (β = 0.165; p = 0.044),
Cre (β = 0.243; p = 0.004), and log-hs-CRP (β = 0.236;
p = 0.005) were independent predictors of resistin
values for hypertensive patients.
Adjustment of the factors significantly associated with
PAD (smoking, age, Cre, eGFR, hs-CRP, and resistin) on
multivariate logistic regression analysis revealed that in-
creased serum resistin level (odds ratio [OR], 1.176; 95%
confidence interval [CI], 1.028–1.345; p = 0.018) was an
independent predictor of PAD in hypertensive patients
(Table 4); plotting of the ROC curve for PAD prediction
revealed that the AUC for resistin was 0.870 (95% CI,
0.798–0.923; p < 0.001) (Fig. 1).
Discussion
The results of this study showed that hypertensive pa-
tients with PAD were older and had higher serum Cre,
Table 2 Clinical characteristics and serum resistin levels of 124
hypertensive patients
Characteristic Number (%) Resistin (ng/mL) p value
Sex Male 82 (66.1) 7.26 (5.10–10.11) 0.631
Female 42 (33.9) 6.95 (5.60–11.98)
Diabetes No 61 (49.2) 6.86 (5.12–10.01) 0.472
Yes 63 (50.8) 7.41 (5.24–10.89)
Dyslipidemia No 25 (20.2) 7.23 (5.14–9.55) 0.818
Yes 99 (79.8) 7.18 (5.20–10.89)
ACE inhibitor No 80 (64.5) 7.17 (5.14–10.81) 0.938
Yes 44 (35.5) 7.22 (5.26–10.16)
ARB No 57 (46.0) 7.20 (4.91–10.44) 0.833
Yes 67 (54.0) 7.18 (5.24–10.19)
β-blocker No 52 (41.9) 6.95 (5.34–9.22) 0.491
Yes 72 (58.1) 7.39 (4.94–11.74)
CCB No 68 (54.8) 7.04 (4.67–10.16) 0.498
Yes 56 (45.2) 7.42 (5.40–10.79)
Statin No 55 (44.6) 7.41 (5.68–10.55) 0.260
Yes 69 (55.4) 6.88 (4.77–10.02)
Fibrate No 94 (75.8) 7.33 (5.36–10.51) 0.253
Yes 30 (24.2) 6.76 (4.56–8.56)
Aspirin No 52 (41.9) 8.90 (5.78–10.24) 0.525
Yes 72 (58.1) 7.88 (4.92–10.16)
Clopidogrel No 94 (75.8) 8.53 (5.36–10.17) 0.253
Yes 30 (24.2) 7.61 (4.56–8.56)
Data are expressed as median and interquartile range after analysis by the
Mann–Whitney U test
ACE angiotensin-converting enzyme, ARB angiotensin-receptor blocker,
CCB calcium-channel blocker
*Values of p < 0.05 were considered statistically significant after analysis by the
Mann–Whitney U test
Table 3 Correlation between serum resistin levels and clinical
variables among the 124 hypertensive patients
Variable Log-Resistin (ng/mL)
Univariate Multivariate
r p Beta p
Age (years) 0.135 0.135 - -
Height (cm) 0.006 0.949 - -
Body weight (kg) −0.117 0.197 - -
Waist circumference (cm) 0.261 0.003* 0.204 0.014*
Body mass index (kg/m2) −0.149 0.098 - -
SBP (mmHg) −0.102 0.261 - -
DBP (mmHg) 0.044 0.629 - -
Total cholesterol (mg/dL) 0.182 0.043* - -
Log-Triglyceride (mg/dL) 0.015 0.872 - -
HDL-C (mg/dL) 0.061 0.501 - -
LDL-C (mg/dL) 0.190 0.035* 0.165 0.044*
Log-glucose (mg/dL) −0.059 0.517 - -
Blood urea nitrogen (mg/dL) 0.237 0.008* - -
Creatinine (mg/dL) 0.298 0.001* 0.243 0.004*
eGFR (mL/min) −0.278 0.002* - -
Total calcium (mg/dL) −0.094 0.302 - -
Phosphorus (mg/dL) −0.109 0.228 - -
Log-iPTH (pg/mL) 0.146 0.106 - -
Log-hs-CRP (mg/dL) 0.294 0.001* 0.236 0.005*
Data of resistin, triglyceride, glucose, iPTH, and hs-CRP levels showed a skewed
distribution and were, therefore, log-transformed before analysis
Analysis of the data was done using the univariate linear regression analyses
or multivariate stepwise linear regression analysis (adopted factors: waist
circumference, total cholesterol, blood urea nitrogen, creatinine, eGFR,
and hs-CRP)
SBP systolic blood pressure, DBP diastolic blood pressure, HDL-C high density
lipoprotein-cholesterol LDL-C low-density lipoprotein cholesterol, eGFR estimated
glomerular filtration rate, iPTH intact parathyroid hormone, hs-CRP high-sensitivity
C-reactive protein
*Values of p < 0.05 were considered statistically significant
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hs-CRP, and resistin levels but a lower eGFR. Serum
resistin level was an independent clinical predictor of
PAD in hypertensive patients after multivariate analysis.
Among these patients, waist circumference and LDL-C,
Cre, and log-hs-CRP levels were the independent predic-
tors of resistin values.
PAD is a result of the blockage of the arteries supplying
blood to the brain, visceral organs, and the limbs and usu-
ally occurs secondarily to atherosclerosis [15, 16]. The
prevalence of PAD increases sharply with age, and it affects
a substantial proportion of the elderly population [1–3].
Moreover, men and women from low- and middle-income
countries have modestly lower PAD rates than those in
high-income countries [1]. The prevalence in high-income
countries at age 45–49 years was 5.28% in women and
5.41% in men; at age 85–89 years, it was 18.38% in women
and 18.83% in men. The prevalence in men was lower in
low- and middle-income countries than in high-income
countries (2.89% at 45–49 years and 14.94% at 85–89
years) [1]. The prevalence in Asian-Americans at age
60–69 years was 2.6% in women and 10.2% in men;
at age ≥ 80 years, it was 17.1% in women and 13.8%
in men [17].
Most studies found a significant independent associ-
ation between hypertension and PAD. The odds ratio of
hypertension for PAD was 1.32–2.20 [3]. The mean age
in this study was 64.4 years and the prevalence was
14.5% in hypertensive patients; of note, hypertensive pa-
tients with PAD tended to be older. Male gender, smoking,
and comorbid diabetes or dyslipidemia are established risk
factors for PAD [2, 3, 16]. Our results also noted current
smokers among low ABI group were significantly higher
than the normal ABI group. Our study did not find statis-
tically significant differences in gender or co-existing dia-
betes or dyslipidemia in hypertensive patients, possibly
due to an insufficient sample size.
A high prevalence of PAD is noted in the US popula-
tion > 40 years old with renal insufficiency, and even
after the adjustment for important confounding factors,
persons with renal insufficiency are still more than twice
as likely to have an ABI < 0.9 according to the National
Health and Nutrition Examination Survey 1999–2000
[18]. Renal insufficiency was also independently associ-
ated with future PAD events among postmenopausal
women with coronary heart disease. The hazard ratio for
PAD in women with a Cre clearance 30–59 mL/min/
1.73 m2, < 30 mL/min/1.73 m2 is 1.63, 3.24 compared
with persons with a Cre clearance ≥ 60 mL/min/1.73 m2
[19]. Our results also noted that hypertensive patients in
the low ABI group had higher serum Cre levels and a
lower eGFR. Inflammatory markers such as CRP are as-
sociated with PAD in many studies [2, 3]. Wildman et al.
noted that the adjusted OR of PAD associated with the
highest versus the lowest quartile of CRP was 2.14 in a
sample of 4,787 participants aged > 40 years in the
National Health and Nutrition Examination Survey
1999–2002 [20]. CRP was associated with fatal and non-
fatal cardiovascular disease events as well as nonfatal
PAD events in 18,450 apparently healthy participants in
the European Prospective Investigation into Cancer and
Nutrition-Norfolk cohort [21]. The hs-CRP level was
also statistically significantly more correlated in PAD pa-
tients, who were at higher risk for CV morbidity and
mortality in the presence of an elevated hs-CRP level
[22]. Similar to these studies, our study revealed that
hypertensive patients with a low ABI had higher serum
hs-CRP levels.
Resistin is an adipokine involved in glucose homeosta-
sis, lipid metabolism, and insulin action [23–25]. Circu-
lating resistin levels have been positively associated with
central obesity as well as insulin resistance in rodents;
however, their significance remained controversial in hu-
man studies [25]. Resistin was positively associated with
waist circumference and insulin resistance and inversely
Fig. 1 The area under the receiver operating characteristic curve
indicates the diagnostic power of resistin for predicting peripheral
artery disease of hypertensive patients
Table 4 Multivariate logistic regression analysis of the factors
correlated to peripheral artery disease among the 124
hypertensive patients




(each increase of 1 ng/mL)
1.176 1.028-1.345 0.018*
Analysis of the data was done using multivariate logistic regression analysis
(adopted factors: smoking, age, creatinine, estimated glomerular filtration
rate, high-sensitivity C-reactive protein, and resistin)
*Values of p < 0.05 were considered statistically significant
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associated with TCH, HDL-C, and LDL-C after adjust-
ment for age, gender, and BMI in a study with 1,508
Finnish subjects aged 45–74 years [26]. In an Indian
study, plasma resistin levels were also positively associ-
ated with waist circumference and insulin resistance.
Moreover, plasma resistin levels were strongly positively
correlated with TCH, HDL-C, and LDL-C levels [27].
Our results also noted that serum resistin levels were
positively associated with waist circumference and LDL-C
level after multivariate linear regression analysis. Human
resistin was shown to be predominantly expressed in per-
ipheral blood mononuclear cells, macrophages, and bone
marrow cells by analyses of resistin gene expression across
a wide array of human tissues [5, 23].
Human resistin is an inflammatory biomarker that
functions through the nuclear factor-κB and other sig-
naling pathways that induce pro-inflammatory processes
[6, 25]. Plasma resistin levels are positively associated
with CRP and predictive of coronary atherosclerosis in
humans [28]. A high serum resistin level is associated
with a low eGFR in patients with type 2 diabetes and
those with chronic kidney disease [29, 30]. High plasma
resistin levels were independently associated with a
greater risk of kidney function decline in middle-aged
and elderly Chinese patients [31]. Our results showed
that serum Cre and log-hs-CRP levels were positively
correlated with serum resistin levels in hypertensive pa-
tients after multivariate analysis.
Resistin has a pathogenic role in the development and
progression of atherosclerosis [6, 23]. Atherosclerosis is
the major cause of PAD by arterial stenosis or occlusion,
particularly of the lower extremities [15, 16]. Our study
revealed that hypertensive patients in the low ABI group
had higher serum resistin levels compared to those in
the normal ABI group. Adjustment of the confounding
factors on the multivariate logistic regression analysis
revealed that an increased serum resistin level was an in-
dependent predictor of PAD in hypertensive patients.
Use of the ABI test to diagnose PAD has several limi-
tations. Occlusive disease distal to the ankle is not de-
tected by the ABI test, which is also sensitive to the
patient’s height [3]. The other limitation of this study is
that it was an observational, single-center study with a
small sample of hypertensive participants. The use of
anti-hypertensive drugs such as ACEi or ARB or of statins
is beneficial for reducing major adverse cardiovascular
events in patients with PAD and hypertension [32]. How-
ever, evidence of the use of various anti-hypertensive
drugs in people with PAD is poor [33]. Another limitation
is that pharmacological interventions have been shown to
influence resistin levels in humans. The use of amlodipine,
bisoprolol, or indapamide resulted in significantly lower
plasma resistin concentrations after 6 weeks of treatment
[34]. Statin therapy did not result in any significant
changes in plasma resistin concentrations in a meta-
analysis [35]. The current results did not show a correl-
ation between anti-hypertensive drugs, statins, fibrates,
aspirin, or clopidogrel and serum resistin levels. Further
studies are required to elucidate the relationship between
medication use and resistin levels in hypertensive patients.
Conclusions
This study showed that a higher resistin level was an inde-
pendent predictor of the development of PAD in hyper-
tensive patients. In addition, waist circumference, LDL-C,
Cre, and log-hs-CRP were positively associated with resis-
tin values in these patients.
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